Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ionis Pharmaceuticals Inc

NASDAQ: IONS · Life Sciences · 7 alerts · CIK 874015

Ionis Pharmaceuticals Inc stories on ALFA USA NewsRead the news →
Share price
$28.01Close, Nov 16
Market cap
$4.66B
Shares outstanding
166.55MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ionis Pharmaceuticals Inc filings on SEC EDGAR ↗

4:17 PM ET 8-K
Regulatory Approval

Ionis Pharmaceuticals Regulatory Approval

Ionis Pharmaceuticals' partner GSK received FDA approval for HIBSAGO (bepirovirsen) for the treatment of chronic hepatitis B (CHB) in adult patients without cirrhosis. The approval, granted under priority review and Breakthrough Therapy Designation, is based on Phase 3 B-Well trials showing a 19% functional cure rate compared to less than 1% for standard of care. Ionis is eligible to receive regulatory and sales milestone payments plus tiered royalties of 10-12% on net sales.

Counterparty
GSK

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.